Yazar "Aydin, S." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Alteration of serum and cardiac tissue adropin, copeptin, irisin and TRPM2 expressions in DOX treated male rats
    (Informa Healthcare, 2015) Aydin, S.; Eren, M. N.; Kuloglu, T.; Aydin, S.; Yilmaz, M.; Gul, E.; Kalayci, M.
    Doxorubicin (DOX) cardiotoxicity is a significant side effect in cancer survivors. DOX and its metabolites alter cardiac gene expression and affect metabolic energy-related peptides. Adropin, copeptin, irisin and TRPM2 are produced locally in the heart and play a role in energy homeostasis. We investigated the fates of adropin, copeptin, irisin and TRPM2 in serum and cardiac tissues of DOX treated rats. Animals were divided into three groups of six: 1) untreated controls, 2) DOX treated and 3) saline treated. The rats were fed a standard diet ad libitum for 14 days then were sacrificed and heart and serum samples were taken. Adropin, copeptin, irisin levels in tissue homogenates and serum were measured using ELISA. Immunoreactivity of heart tissue adropin, copeptin, irisin and TRPM2 also were investigated. The peptides increased in both serum and cardiac tissue homogenates in animals treated with DOX compared to the other groups. DOX increased adropin in endocardial and myocardial cells, but it decreased expression of copeptin. DOX did not affect endocardial irisin and TRPM2 expressions, but myocardial irisin and TRPM2 expressions were increased. Serum adropin, irisin and copeptin were increased in DOX treated rats. Cardiac adropin, copeptin, irisin and TRPM2 are affected by DOX and may play a role in DOX cardiotoxicity.
  • [ X ]
    Öğe
    Does hepcidin play a role in the pathogenesis of aphthae in Behcet's disease and recurrent aphthous stomatitis?
    (Wiley, 2014) Cicek, D.; Dagli, A. F.; Aydin, S.; Dogan, F. Baskaya; Dertlioglu, S. B.; Ucak, H.; Demir, B.
    BackgroundAphthae constitute one of the major signs in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS). No scientific study has yet explored the relationship of hepcidins, which have antimicrobial effects, with RAS and BD. ObjectivesIn this study, we aimed to evaluate by immunohistochemistry whether hepcidin is synthesized by the salivary glands and to measure levels of prohepcidin and hepcidin (an antibacterial peptide) in the serum and saliva of patients with BD and RAS. MethodsThe study included 25 BD patients and 30 RAS patients, as well as a control group comprising 25 healthy individuals. Serum and saliva samples were collected at the same time from all subjects. Levels of prohepcidin and hepcidin were measured by ELISA. The presence of hepcidin in salivary glands was assessed by immunohistochemistry. ResultsHepcidin was localized in the striated ducts of the sublingual and parotid glands. Saliva prohepcidin and hepcidin levels were correlated with blood levels. Saliva prohepcidin levels were found to be lower in RAS patients than in BD patients and healthy controls (P<0.001 and P=0.007 respectively). In addition, RAS patients had lower saliva hepcidin levels than did the control group (P=0.03). ConclusionsThe lower serum and saliva prohepcidin and hepcidin concentrations found in RAS and BD patients indicate that hepcidin may be involved in the aetiopathogenesis of these diseases. Because it can be obtained non-invasively and easily, saliva may provide a useful alternative to serum in quantifying prohepcidin and hepcidin concentrations.
  • [ X ]
    Öğe
    Serum Ghrelin Levels in Patients with Chronic Urticaria and Atopic Dermatitis and Its Relationship with Metabolic Syndrome
    (Univ West Indies Faculty Medical Sciences, 2023) Demir, B.; Cicek, D.; Dertlioglu, S.; Aydin, S.; Ucak, H.; Ergin, C.; Erden, I.
    Objective: Chronic urticaria is a systemic inflammatory disease. Atopic dermatitis is a chronic immunological disease that is characterized by an increase in systemic inflammatory response. In several studies, chronic urticaria and atopic dermatitis were reported to be associated metabolic syndrome (MetS). In this study, we aimed to investigate the serum ghrelin levels in the patients with chronic urticaria and atopic dermatitis. Methods: Thirty patients with chronic urticaria, 30 patients with atopic dermatitis and 30 control subjects participated in this study. Blood fasting glucose and serum lipids, insulin, C-peptide levels and thyroid function tests were measured. The homeostasis model assessment of insulin resistance (HOMA-IR) was used to calculate insulin resistance. Ghrelin levels were determined by an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's protocol. Results: The mean serum ghrelin levels in the patients with chronic urticaria (54.13 +/- 40.94 pg/mL) and atopic dermatitis (65.33 +/- 93.54 pg/mL) were significantly higher than those of the controls (30.36 +/- 17.13 pg/mL) (p = 0.003, p = 0.04, respectively). Conclusion: We detected higher serum ghrelin levels in the patients with chronic urticaria and atopic dermatitis than the controls. However, we failed to find any association between serum ghrelin levels and insulin resistance or MetS. We think that the high levels of serum ghrelin in the patients with chronic urticaria and atopic dermatitis may be related to the mechanisms independent of insulin resistance.